Protease Inhibitors in Neurologic Diseases
Publisher
Springer New York
Reference46 articles.
1. J.P. Antel, E. Chelmicka Schorr, M. Sportiello, K. Stefansson, R.L. Wollman, and B. G. W. Arnason, Muscle acid protease activity in amyotrophic lateral sclerosis: correlation with clinical and pathologic features. Neurology, 32: 901–903 (1982).
2. R.L. Beach, L.S.Rao, B.W.Festoff, E.T. Reyes, R.Yanagihara, and D. C.Gajdusek, Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis. J. NeuroL Sci, 72: 49–60 (1986).
3. B.W. Festoff, Circulating protease inhibitors in amyotrophic lateral sclerosis: reduced a2 macroglobulin. Ann. NeuroL, 8: 121 (1980).
4. B.W. Festoff, Occurrence of reduced aZ macroglobulin and lowered protease inhibiting capacity in plasma of amyotrophic lateral sclerosis patients. Ann. N.Y. Acad Sci., 421: 369–376 (1983).
5. N. Adachi, and S. Shoji, Studies of protease inhibitors in the sera of patients with amyotrophic lateral sclerosis. J. NeuroL Sci., 89: 165–168 (1989).